249 related articles for article (PubMed ID: 19064407)
1. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
2. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
3. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
4. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
5. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.
Jiang Y; Kimchi ET; Staveley-O'Carroll KF; Cheng H; Ajani JA
Cancer; 2009 Aug; 115(16):3609-17. PubMed ID: 19526592
[TBL] [Abstract][Full Text] [Related]
6. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Van Cutsem E
Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
9. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
Engstrom PF;
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
[TBL] [Abstract][Full Text] [Related]
11. Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.
Macarulla T; Ramos FJ; Elez E; Capdevila J; Peralta S; Tabernero J
Clin Colorectal Cancer; 2008 Sep; 7(5):300-8. PubMed ID: 18794061
[TBL] [Abstract][Full Text] [Related]
12. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
Serrano C; Markman B; Tabernero J
Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
14. [Colorectal carcinoma--molecular markers in clinical routine].
Tannapfel A; Reinacher-Schick A
Onkologie; 2008; 31 Suppl 5():1-2. PubMed ID: 19033696
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy for metastatic colorectal cancer].
Iwasa S; Shimada Y
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1467-74. PubMed ID: 18799899
[TBL] [Abstract][Full Text] [Related]
17. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
Dasari A; Messersmith WA
Clin Cancer Res; 2010 Aug; 16(15):3811-8. PubMed ID: 20554751
[TBL] [Abstract][Full Text] [Related]
18. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
19. The epidermal growth factor receptor pathway: a model for targeted therapy.
Scaltriti M; Baselga J
Clin Cancer Res; 2006 Sep; 12(18):5268-72. PubMed ID: 17000658
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
Wallerand H; Reiter RR; Ravaud A
Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
